Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 17/20 | 0.40 |
| ▸ | SCN1A | P35498 | 15/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 11/20 | 0.40 |
| ▸ | SCN1B | Q07699 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19613506 | 0.92 | SCN8A (0.41) | SCN8ASCN1ASCN5ASCN1BNR1I2 | |
| SCHEMBL19613447 | 0.87 | ACLY (0.44) | SCN8ASCN1ASCN5ASCN1BNR1I2 | |
| SCHEMBL19631526 | 0.86 | SCN8A (0.41) | SCN8ASCN1ASCN5ASCN1BNR1I2 | |
| SCHEMBL20252602 | 0.84 | NOS3 (0.34) | SCN8ASCN1ASCN5AACLY | |
| SCHEMBL20252608 | 0.84 | EGFR (0.33) | SCN8ASCN1ASCN5ASCN1BNR1I2 | |
| SCHEMBL19631543 | 0.84 | SCN8A (0.39) | SCN8ASCN1ASCN5ASCN1BNR1I2 | |
| SCHEMBL20252647 | 0.84 | ALDH1A1 (0.33) | SCN8ASCN1ASCN5ASCN9AACLY | |
| SCHEMBL20252576 | 0.83 | SCN8A (0.53) | SCN8ASCN1ASCN5ASCN1BNR1I2 | |
| SCHEMBL18352662 | 0.82 | LMNA (0.34) | SCN8ASCN1ASCN5ASCN1BNR1I2 | |
| SCHEMBL16185274 | 0.82 | MEN1 (0.33) | ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | SCN8A 14/4885SCN1A 1/4885SCN5A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.